Summary:
- The article explores the advancement of programmable medicines, specifically focusing on how synthetic biology and genetic engineering are being utilized to create "smart" therapies that target cancer cells with high precision.
- It discusses the shift from traditional, broad-spectrum chemotherapy toward modular, logic-gated therapeutic platforms—such as CAR-T cells and synthetic gene circuits—that can sense specific intracellular environments and trigger a targeted biological response.